Advertisement
Review article| Volume 23, ISSUE 2, P385-394, June 2003

Download started.

Ok

Prenatal screening for open neural tube defects

  • Jacob A Canick
    Correspondence
    Corresponding author
    Affiliations
    Division of Prenatal and Special Testing, Department of Pathology and Laboratory Medicine, Women and Infants Hospital, Brown Medical School, 101 Dudley Street, Providence, RI 02905-2401, USA
    Search for articles by this author
  • Leonard H Kellner
    Affiliations
    Lenetix Medical Laboratories Inc., 938 Roosevelt Street, Franklin Square, New York, NY 11010, USA

    Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, USA
    Search for articles by this author
  • Allan T Bombard
    Affiliations
    Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, USA

    Department of Obstetrics and Gynecology, Lutheran Medical Center, 150 55th Street, Suite 3526, Brooklyn, NY 11220, USA
    Search for articles by this author
      The era of prenatal screening for serious birth defects began in the 1970s with the discovery that amniotic fluid and maternal serum levels of alpha-fetoprotein (AFP) were increased in pregnancies affected by fetal open neural tube defects [
      • Wald N.J.
      • Cuckle H.S.
      Open neural-tube defects.
      ]. Since then, prenatal screening has become a part of routine obstetric care. In this article, the use of AFP in prenatal screening for open neural tube defects is discussed in the context of the laboratory and the laboratory's interactions with the practicing obstetrician.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wald N.J.
        • Cuckle H.S.
        Open neural-tube defects.
        in: Wald N.J. Antenatal and neonatal screening. Oxford University Press, Oxford1984: 25-73
        • Greenberg F.
        • James L.M.
        • Oakley G.P.
        Estimates of birth prevalence rates of spina bifida in the United States from computer-generated maps.
        Am J Obstet Gynecol. 1983; 145: 570-573
        • Johnson A.M.
        Racial differences in maternal serum screening.
        in: Mizejewski J.G. Porter I.H. Alpha-fetoprotein and congenital disorders. Academic Press, New York1985: 183-196
        • Wald N.J.
        Folic acid and neural tube defects: the current evidence and implications for prevention.
        in: Bock G. Marsh J. Neural tube defects, CIBA Foundation Symposium 181. Wiley, Chichester1994: 192-211
        • Wald N.J.
        The detection of neural-tube defects by screening maternal blood.
        in: Boue A. Prenatal diagnosis. INSERM, France1976: 227-238
        • Bergstrand C.G.
        • Czar B.
        Demonstration of a new protein fraction in serum from the human fetus.
        Scand J Clin Lab Invest. 1956; 8: 174
        • Haddow J.E.
        Biologic properties of alpha-fetoprotein in detection of fetal disorders.
        in: Elias S. Simpson J.L. Maternal serum screening for fetal genetic disorders. Churchill Livingstone, New York1992: 25-40
        • Brock D.J.H.
        • Sutcliffe R.G.
        Alpha-fetoprotein in the antenatal diagnosis of anencephaly and spina bifida.
        Lancet. 1972; ii: 197-199
        • Hino M.
        • Koki Y.
        • Nishi S.
        Nimpu ketsu naka no alpha-fetoprotein.
        Igaku No Ayumi. 1972; 82: 512-513
        • Brock D.J.H.
        • Bolton A.E.
        • Monoghan J.M.
        Prenatal diagnosis of anencephaly through maternal serum-alphafetoprotein measurement.
        Lancet. 1973; ii: 923
        • Leek A.E.
        • Ruoss C.F.
        • Kitau M.J.
        • Chard T.
        Raised alpha-fetoprotein in maternal serum with anencephalic pregnancy.
        Lancet. 1973; 2: 385
        • Wald N.J.
        • Brock D.J.H.
        • Bonner J.
        Prenatal diagnosis of spina bifida and anencephaly by serum alpha-fetoprotein measurement.
        Lancet. 1974; i: 765-767
        • Brock D.J.H.
        • Bolton A.E.
        • Scrimgeour J.B.
        Prenatal diagnosis of spina bifida and anencephaly through maternal plasma alpha-fetoprotein measurement.
        Lancet. 1974; i: 767-769
        • Wald N.
        Neural tube defects.
        in: Wald N. Leck I. Antenatal and neonatal screening. 2nd edition. Oxford University Press, Oxford2000: 61-84
        • Haddow J.E.
        • Kloza E.M.
        • Knight G.J.
        • Smith D.E.
        Relationship between maternal weight and serum alpha-fetoprotein concentration during the second trimester.
        Clin Chem. 1981; 27: 133-134
        • Wald N.J.
        • Cuckle H.
        • Boreham J.
        • Terzian E.
        • Redman C.
        The effect of maternal weight on maternal serum alpha-fetoprotein levels.
        Br J Obstet Gynaecol. 1981; 88: 1094-1096
        • Wald N.J.
        • Cuckle H.S.
        Recent advances in screening for neural tube defects and Down's syndrome.
        Ballieres Clin Obstet Gynaecol. 1987; 1: 649-676
        • Watt H.C.
        • Wald N.J.
        • Smith D.
        • Kennard A.
        • Densem J.
        Effect of allowing for ethnic group in prenatal screening for Down's syndrome.
        Prenat Diagn. 1996; 16: 691-698
        • Knight G.J.
        • Palomaki G.E.
        Maternal serum alpha-fetoprotein and the detection of open neural tube defects.
        in: Elias S. Simpson J.L. Maternal serum screening for fetal genetic disorders. Churchill Livingstone, New York1992: 41-58
        • Crandall B.F.
        Prenatal screening for the detection of neural tube defects.
        in: Simpson J.L. Elias S. Essentials of prenatal diagnosis. Churchill Livingstone, New York1993: 253-274
        • Haddow J.E.
        • Goldfine C.
        The evolving role of amniotic fluid gel acetylcholinesterase analysis for identifying open fetal defects during the second trimester.
        in: Mizejewski J.G. Porter I.H. Alpha-fetoprotein and congenital disorders. Academic Press, New York1985: 215-237
        • Nadel A.
        • Green J.K.
        • Holmes L.B.
        • Frigoletto F.D.
        • Benacerraf B.R.
        Absence of need for amniocentesis in patients with elevated levels of maternal serum alpha-fetoprotein and normal ultrasonographic examinations.
        N Engl J Med. 1990; 323: 557-561
        • Platt L.D.
        • Feuchtbaum L.
        • Filly R.
        • Lustig L.
        • Simon M.
        • Cunningham G.C.
        The California maternal serum alpha-fetoprotein screening program: the role of ultrasonography in the detection of spina bifida.
        Am J Obstet Gynecol. 1992; 166: 1328-1329
        • Nicolaides K.H.
        • Campbell S.
        • Gabbe S.G.
        • Guidetti R.
        Ultrasound screening for spina bifida: cranial and cerebellar signs.
        Lancet. 1986; ii: 72-74
        • Wald N.J.
        • Hackshaw A.K.
        • Cuckle H.S.
        Maternal serum alpha-fetoprotein screening for open neural tube defects: revised statistical parameters.
        Br J Obstet Gynaecol. 2000; 107: 296-298

      Linked Article